Vaccines against cervical cancer

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 570-574

  Rogers, Linda J ^a   Eva, Lois J ^a   Luesley, David Michael ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer; Human papillomavirus; Prophylactic vaccine; Therapeutic vaccine

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE;

CANCER GRADING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; HEALTH CARE DELIVERY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MARKET; NONHUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; FEMALE; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 59649122872     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328303e2a1     Document Type: Review

References (14)

1. Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007; 7:1473-1486.
2. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39:679-689.
3. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007; 85:719-726.
4. Giarelli E. Cancer vaccines: a new frontier in prevention and treatment. Oncology 2007; 21:11-17.
5. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007; 107:S19-S23.
6. The FUTURE II Study Group. Quadrivalent vaccine against human papillo-mavirus to prevent high-grade cervical lesions. NEJM 2007; 356:1915-1927. This study reports the results of a phase 3 trial that was conducted to evaluate the efficacy of the quadrivalent HPV vaccine.
7. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007; 107:S31-S33.
8. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomised controlled trial. Obstet Gynecol 2006; 107:18-27.
9. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.
10. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006; 367:1247-1255.
11. The HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170. This study reports the interim analysis of a phase three study that was conducted to evaluate the efficacy of the bivalent HPV vaccine.
12. HPV and vaccines: technical information for policy makers and health professionals. www.who.int/vaccines-documents/DocsPDF07/866.pdf.
13. Goldie SJ, Kim JJ, Kobus KE, et al. Cost effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 2007; 25:6257-6270.
14. Kane MA, Sherris J, Coursaget P, et al. HPV vaccine use in the developing world. Vaccine 2006; 24 (suppl 3):S132-S139.